This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

The Pathogenic Effect of IgG4 Autoantibodies in Endemic Pemphigus Foliaceus (Fogo Selvagem)

List of authors.
  • Barbara Rock, M.D.,
  • Ciro R. Martins, M.D.,
  • Argyrios N. Theofilopoulos, M.D.,
  • Robert S. Balderas,
  • Grant J. Anhalt, M.D.,
  • Ramzy S. Labib, M.D., Ph.D.,
  • Shozo Futamura, M.D.,
  • Evandro A. Rivitti, M.D.,
  • and Luis A. Diaz, M.D.

Abstract

Endemic pemphigus foliaceus, or fogo selvagem, is an autoimmune blistering skin disease caused by IgG autoantibodies to a desmosome-associated glycoprotein. We studied the IgG subclasses with autoantibody activity in serum from 29 patients with active disease and in the skin lesions of 18 patients by immunofluorescence, using IgG-subclass–specific monoclonal antibodies. The predominant disease autoantibodies present in all patients were of the IgG4 subclass. IgG1 and IgG2 autoantibodies were detected in low titer in the 29 patients: IgG1 in 23 patients and IgG2 in 9. IgG3 autoantibodies were not detected in the serum of any patient. Direct immunofluorescence testing of skin lesions showed a preferential deposition of IgG4 on the keratinocyte surface.

The pathogenic effect of IgG4 was demonstrated by the passive transfer of fractions containing IgG4 autoantibodies from the patients to neonatal BALB/c mice. The disease of the patients was reproduced clinically, histologically, and immunologically in these animals. Only IgG4 autoantibodies were detected by direct immunofluorescence, bound to the epidermis in the lesions of the mice, and by immunoelectron microscopy at the keratinocyte surface.

IgG4 has previously been reported to be a blocking or protective antibody because it has poor effector functions in vitro, as compared with the other IgG subclasses. The finding that it is the pathogenic autoantibody in fogo selvagem raises the possibility that it may also be important in other autoimmune disease. (N Engl J Med 1989; 320: 1463–9.)

Funding and Disclosures

Supported in part by grants (RO1-AR-32599, RO1-AR-32081, FO6-TW-12222–01, RO1-AR-32490, KO4-AR-01686, T32-AR-07324, AR-33826, and AR-31203) from the U.S. Public Health Service and by a grant (AI-07007) from the National Institutes of Health. Dr. Martins is a postdoctoral fellow supported by the Rotary Foundation of Rotary International.

Presented in abstract form at a meeting of the Society of Investigative Dermatology, Washington, D.C., April 27, 1988.

Author Affiliations

From the Departments of Dermatology, Johns Hopkins University, Baltimore (B.R., G.J.A., R.S.L., S.F.), the University of São Paulo, São Paulo, Brazil (C.R.M., E.A.R.), and the Medical College of Wisconsin, Milwaukee (L.A.D.); and the Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, Calif. (A.N.T., R.S.B.). Address reprint requests to Dr. Diaz at the Department of Dermatology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Milwaukee, WI 53226.

Print Subscriber? Activate your online access.